During the course of the current pandemic, tests have been widespread and easy to access. But testing is obviously not enough, and adequate treatment after a positive diagnosis has almost never been paired with that test.

This is where Todos Medical is making a difference: by pairing a positive test with treatment, or Test to Treat. The current presidential administration announced a nationwide Test to Treat initiative in March, and Todos Medical is well positioned to benefit from this push.

Todos Medical aims to pair its testing expertise with Tollovir™, its oral antiviral for acute infections. It is a Phase 2/3 candidate specifically for acute infections that inhibits the 3 CL protease and cytokine storms, making it a strong potential solution for a test-to-treat strategy.

Lingering impacts from those who tested positive during the recent pandemic has been a pervasive problem. The effects that these “long haulers” suffer through can be different for everyone and can affect many different parts of the body, such as the heart, brain, and lungs. Additionally, these effects may come and go, and they may last for a few weeks, a few months, or longer, leading to significant disruptions in lives.

Todos believes it has a real solution for PASC (post-acute sequelae of C-19) with Tollovid™. They are compiling 35+ individual case studies with long hauler participants as their physicians monitor their symptoms and progress on Tollovid™ over 30, 60, and 90 day periods. They are also conducting a randomized, observer blinded, non-exposure control study to evaluate the safety of TollovidTM and Tollovid’s effects on the structure/function of the immune system in subjects with PASC.

100% of acute C-19 respondents reported a decrease in acute C-19 symptoms, with very significant decreases in chronic long hauler symptoms reported as well. We encourage you to check out their case studies here and here. Below is data on the potential US market alone:

3CL Protease Inhibitors: The Potential Key to Combating the SARS-CoV-2 Virus Life Cycle

The stages in the virus life cycle include binding, entry, breakdown of proteins into smaller polypeptides or amino acids, and RNA replication.

SARS-CoV-2, like any other virus, is a single strand of RNA (or DNA) wrapped in a protein envelope. The RNA contains the genetic instructions the virus needs to make copies of itself.

Viruses spread with a simple two-step process:

I. Break into a healthy cell

II. Hijack the cell’s own mechanisms to make copies of itself

Studies have shown, however, that by using protease inhibitors, we can stop the virus’ ability to replicate itself, halting the spread in it tracks. To understand how this is done, let’s take a closer look at the COVID virus lifecycle:

1. First, the virus must get inside the cell. Every virus does this slightly differently, but coronaviruses (such as SARS-CoV-2) use their signature “spikes” to fuse themselves to a cell’s outer wall and then squeeze their way inside.

2. Once inside, the virus RNA converts into a polypeptide. This long protein is like a bus for the team of enzymes whose job it is to make more of the virus.

3. Before these enzymes can start working, they need to be separated from each other. The protease enzyme acts like a pair of scissors, cutting the polypeptide up into the different enzymes that then become functional.

4. When the protease enzyme comes in contact with a protease inhibitor, it is prevented from functioning. Protease inhibitor drugs are designed to tightly bind to the protease enzyme, blocking its ability to cleave. This shuts down the entire virus-making apparatus, leaving it unable to make a single virus.

Blood based tests are the future of diagnostics screening. Our TBIA platform represents a cost effective, scalable, and patient friendly screening method for cancer detection.

Videssa® Breast: Cancer Blood Test

• Designed specifically for the early detection of breast cancer in women with abnormal imaging findings

• A simple blood test to detect breast cancer with high accuracy in women with abnormal imaging findings

• A protein-based blood test combining Serum protein biomarkers (SPBs) with Tumor Associated Autoantibodies (TAAbs).

LymPro™: Alzheimer's Blood Test: The High Potential of Measuring Lymphocyte Proliferation

The Lymphocyte Proliferation (LymPro) Test™ measures the immune proliferative response of white blood cells to mitogenic stimulation. Based on differences observed in the response of cells from patients with Alzheimer’s disease as compared with age-matched controls and patients with other dementias, it appears that the test has high potential as an adjunctive diagnostic for Alzheimer’s disease. Deployment includes initial IUO testing followed by full diagnostic testing for patients with MCI and dementia for differential diagnosis.

TolloTest™: A Coronavirus 3CL Protease Test

• TolloTest™ is a diagnostic test that measures the 3CL protease from upper respiratory samples.

• The 3CL protease is the main protease found in coronaviruses. It cleaves the coronavirus polyprotein at eleven conserved sites. It is a cysteine protease and a member of the PA clan of proteases. The 3CL protease is required for the replication of coronaviruses. Todos is using the 3CL protease biomarker as a new measure for viral load/contagiousness. This could provide clearer objective data to make end of quarantine decisions, when many PCR positive patients are likely inappropriately released from quarantine and able to infect others, or are inappropriately forced to quarantine due to continued positive PCR tests, when in fact they are no longer contagious due to the absence of 3CL protease. Todos is also using TolloTest as a surrogate marker to evaluate the ability of its COVID-19 antiviral 3CL protease inhibitor drug candidate Tollovir™ to reduce the SARS-CoV-2 virus.

TBIA: AI Cancer Platform: Reading the Immune Response to Cancer

• The Next Gen Early Detector

• Today’s battery of screenings are conducted too rarely or too late in the disease’s progression to allow for the most effective treatment.

• Evidence suggests that blood-based tests are the future of cancer screening. Our TBIA platform, represents a cost-effective, scalable, and patient-friendly screening practice for cancer detection.

Todos Medical has acquired exclusive distribution rights to the dietary supplement Tollovid™. It is the only known commercial product to directly inhibit the underlying mechanism of the 3CL protease based on in vitro studies in multiple labs, which has shown strong promise for acute infections.




Tollovid is a powerful proprietary blend of plant extracts that help support healthy immune function for today's challenges.

BENEFITS:

• The healthy way to support your immune system.

• High in antioxidants and may fight inflammation and boost skin health.

• Plant-based and vegan-friendly.

• Scientifically studied.

• Traceable ingredients.

• Made in the USA at a cGMP FDA Regulated Facility.

Head to https://mytollovid.com/ for more information, testimonials and case studies.

With potential solutions in both the testing and treatment markets, Todos Medical has multiple channels for potential market disruption and revenue generation.

The Acute Infection Market in the US:

Testing Market:

The Supplement Market:

Watch how Todos Medical is partnering with Meadowlands Diagnostics to implement an automated solution to maximize processing capacity to 6,000 PCR tests per day.

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

Todos Medical Ltd. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment. 

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.